Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Molecular markers in peripheral blood mononuclear cells for early diagnosis of non-small cell lung cancer

A non-small cell lung cancer, auxiliary diagnosis technology, applied in the biological field, can solve problems such as single diagnostic feature

Active Publication Date: 2022-03-08
ACADEMY OF MILITARY MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no single diagnostic feature emerged between the various reports
Although the existing NSCLC diagnostic markers have some diagnostic effect, there are still several tasks to be solved, and additional external validation is required to determine a standard collection protocol and confirm the gene signature and its accuracy. A larger prospective cohort study of untreated patients to more fully determine potential confounding effects or the role of disease and to assess the overall clinical feasibility and utility of this approach

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular markers in peripheral blood mononuclear cells for early diagnosis of non-small cell lung cancer
  • Molecular markers in peripheral blood mononuclear cells for early diagnosis of non-small cell lung cancer
  • Molecular markers in peripheral blood mononuclear cells for early diagnosis of non-small cell lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0126] Example 1. Discovery of molecular markers for early diagnosis of non-small cell lung cancer

[0127] 1. Detection of the expression levels of CD86, CD226, CD247 and ICAM-1 in PBMCs of patients in the experimental group

[0128] 1) Clinical data of the subjects in the experimental group

[0129] The experimental group included 105 patients with non-small cell lung cancer (NSCLC group) and 20 patients with benign lung nodules (BENIGN group). The NSCLC group (91.4% for stage I, 4.8% for stage II, 2.9% for stage III, 0 for stage IV, 0.9% unknown) included 87 (82.9%) with adenocarcinoma and 18 (17.1%) with squamous cell carcinoma. The specific clinical information is shown in Table 7. It can be seen that there is no difference between the NSCLC group and the BENIGN group in terms of age, sex and smoking (all P values ​​are greater than 0.05).

[0130] Table 7 is a list of clinical data of the subjects in the experimental group

[0131]

[0132]

[0133] NOTE: P-valu...

Embodiment 2

[0183] Example 2, the application of the expression of CD226 and CD247 in detecting whether the examinee suffers from non-small cell lung cancer

[0184] 1. Detection of the expression levels of CD226 and CD247 in the PBMC of the subject

[0185] 1. Separation and detection of the PBMC of the examinee: 32 cases of non-small cell lung cancer (pathological diagnosis is in the I stage) and 17 patients with benign pulmonary nodules (clinically diagnosed) as the examinee, the method is the same as that of Example 1 Same as 2.1;

[0186] 2. Extraction and purification of total RNA in PBMC: the method is the same as 2.2 of Example 1-1;

[0187] 3. The reverse transcription of the PBMC RNA sample: the method is the same as the 2.3 of the first one of the embodiment 1;

[0188] 4. qRT-PCR:

[0189] Using the reverse-transcribed cDNA in the above 3 as a template, qRT-PCR was performed with primers CD226-F / CD226-R and CD247-F / CD247-R in Table 4, respectively; GAPDH was used as an inte...

Embodiment 3

[0209] Example 3, the application of the expression levels of CD226 and CD247 and the amount of smoking of the examinee in detecting whether the examinee suffers from non-small cell lung cancer

[0210] 1. Detect the expression levels of CD226 and CD247 in the PBMC of the subject

[0211] 1. Separation and detection of the PBMC of the examinee: 32 cases of non-small cell lung cancer (pathologically diagnosed as stage I) and 17 patients with benign pulmonary nodules (clinically diagnosed) as the examinee, the method is the same as that of Example 1 Same as 2.1;

[0212] 2. Extraction and purification of total RNA in PBMC: method is the same as 2.2 of embodiment 1-1;

[0213]3. The reverse transcription of the PBMC RNA sample: the method is the same as the 2.3 of the first one of the embodiment 1;

[0214] 4. qRT-PCR:

[0215] Using the reverse-transcribed cDNA in the above 3 as a template, qRT-PCR was performed with primers CD226-F / CD226-R and CD247-F / CD247-R in Table 4, res...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a molecular marker used in the early diagnosis of non-small cell lung cancer in peripheral blood mononuclear cells. The invention provides a substance for detecting the expression level of the CD226 gene in the PBMC of a subject, a substance for detecting the expression level of the CD247 gene in the PBMC of the subject, and a substance for detecting the amount of smoking of the subject. 1) and / or 2) applications in products with functions: 1) detecting or assisting in detecting whether a subject has non-small cell lung cancer; 2) distinguishing or assisting in distinguishing whether a subject is non-small cell lung cancer or benign lung nodules Patient; the smoking amount is whether the annual smoking amount is greater than 40 packs. Experiments of the present invention have proved that the diagnostic combination composed of CD226, CD247 and the patient's smoking amount (greater than 40 packs / year) can effectively distinguish non-small cell lung cancer patients from benign nodules in the lungs, and is expected to become the first choice for early diagnosis of non-small cell lung cancer. molecular markers.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a molecular marker in peripheral blood mononuclear cells for early diagnosis of non-small cell lung cancer. Background technique [0002] The 2018 global cancer statistics show that lung cancer is still the first malignant tumor in terms of incidence (11.6%) and mortality (18.4%). Due to the accelerated process of industrial development, the aggravation of air pollution and the increase in the number of smokers, the incidence and mortality of lung cancer are increasing year by year, and the situation is very serious. Nearly 85% of all lung cancer cases are non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC), mainly including squamous cell carcinoma, adenocarcinoma, large cell carcinoma and so on. Non-small cell lung cancer has a high degree of malignancy, a low 5-year survival rate, and 70% of patients have advanced lung cancer when they were first diagnosed. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G16B20/00G16B25/10
CPCC12Q1/6886G16B20/00G16B25/10C12Q2600/158C12Q2600/112
Inventor 林艳丽王友亮钟荣斌王启伟吴晓洁靳杰
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com